DNMT3A and acute myeloid leukemia: For a plethora of reasons, DNMT3A might be a key component of leukemogenesis and therefore, an important primary target for therapeutic interventions: DNMT3A mutations occur in ~ 25% of AML patients and are associated with a poor prognosis [11, 12, 62].